CPRIT EXTENSION
Published on November 22, 2019
EXHIBIT 10.1
PORTIONS HEREIN IDENTIFIED BY [*****] HAVE BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE EXCLUDED INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
|
|
Grant ID: DP160012 |
PI/PD/CR: Jeff Hutchins |
No Cost Extension with Attachment F
As indicated by the signatures below, the INSTITUTE and the RECIPIENT agree to the following amendments to the CPRIT Contract:
Original Contract End Date : 31 May 2019
Current Contract End Date : 30 Nov 2019
Proposed Contract End Date : 30 May 2020
Justification: [*****].
Contract Document F: Parties hereby agree that the RECIPIENT is granted a second six-month extension of time from the termination date reflected in the Attachment F-No Cost Extension (Version 1) approved on April 12, 2019, for purposes of concluding the approved scope of work as authorized by the Contract. Accordingly, the November 30, 2019 termination date is replaced with May 30, 2020. All terms and conditions of the Contract continue during the extension period. Parties agree that this extension is a no-cost extension and approval of this amendment does not approve, grant or confer additional grant funds in excess of the amount originally awarded.
Description : The November 30, 2019 termination date is replaced with May 30, 2020 for purposes of concluding the approved scope of work as authorized by the Contract.
|
|
RECIPIENT Pelican Therapeutics ASO Name: Jasuja, Rahul Submitted Date: 09 Sep 2019 |
INSTITUTE Cancer Prevention & Research Institute of Texas CEO Name: Roberts, Wayne Approved Date: 20 Nov 2019 |